RETA
GLP-1R is an investigational triple agonist peptide that targets three receptors: GIP, GLP-1, and glucagon. It is being researched for its potent effects on weight loss and metabolic health, surpassing dual-agonist mechanisms.
Price range: $148.00 through $298.00
The information provided on this page is intended solely as a general summary. It does not encompass all potential research applications, handling procedures, safety precautions, interactions, or observed effects. These products are supplied strictly for laboratory and research purposes only. They are not intended for human consumption, medical use, veterinary use, or diagnostic purposes. This information must not be considered a substitute for professional expertise, judgment, or regulatory guidance.
Money Back Guarantee
Guaranteed Quality
Fast Shipping
10+ Years Experience
Frequently Bought Together
SEQUENCE/FORMULA
MOLECULAR WEIGHT
PUBCHEM CID
- Studying its powerful effects on weight management and metabolic health
- Investigating its advanced ability to control blood sugar and reduce weight
- Analyzing its potential to reduce fat buildup in the liver
- Researching its role in improving heart health markers
- Exploring how it may help the body burn more calories
- Retatrutide is a first-in-class triple-agonist that activates three different hormone receptors involved in metabolism: the GLP-1, GIP, and Glucagon receptors.
- GLP-1 (Glucagon-like peptide-1) Receptor Agonism: This action increases insulin secretion, suppresses appetite, and slows stomach emptying, leading to reduced food intake and improved blood sugar control.
- GIP (Glucose-dependent insulinotropic polypeptide) Receptor Agonism: This action enhances insulin secretion and is believed to improve how the body processes sugar and fat, contributing to weight loss.
- Glucagon Receptor Agonism: This is the unique third mechanism. Activating the glucagon receptor is thought to increase energy expenditure, further promoting weight loss and reducing liver fat.
- The combination of these three mechanisms results in a powerful, synergistic effect on appetite reduction, caloric intake, and energy expenditure, leading to significant weight loss and metabolic improvements.
- Jastreboff, A. M., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 389(6), 514-526.
- Coskun, T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for the treatment of type 2 diabetes and obesity: From discovery to clinical proof of concept. EASD 2022 abstracts, Abstract 58.
- Gallo, M., et al. (2023). Retatrutide for the treatment of obesity: a new GIP/GLP-1/glucagon receptor triagonist. Journal of Experimental Pharmacology, 15, 237–240.
- Urva, S., et al. (2022). The novel GIP/GLP-1/glucagon receptor triagonist retatrutide (LY3437943) for the treatment of type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending-dose trial. The Lancet, 400(10366), 1869-1881.